Close Menu

As its contract with the National Cancer Institute nears completion, startup Mirimus is hoping to begin adding drug companies to the list of customers for its inducible-RNAi mouse models, Mirimus CEO Prem Premsrirut said this week.

At this point, the majority of Mirimus' clients are academics, which have been easier to approach given Mirimus' status as a spinout of Cold Spring Harbor Laboratory, she told Gene Silencing News. “The commercial customers we're aiming for ... will take a little bit more time.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Nov
13
Sponsored by
Agena Bioscience

This webinar will discuss advances in detecting MET and NTRK variants in tumor samples, which can help clinicians determine the appropriate therapy for cancer patients.